Home/Pipeline/Huntington's Disease Program

Huntington's Disease Program

Huntington's Disease

Pre-clinicalActive

Key Facts

Indication

Huntington's Disease

Phase

Pre-clinical

Status

Active

Company

Rumi Scientific

About Rumi Scientific

Rumi Scientific, founded in 2015 and based in New York, is a private biotech company developing a predictive discovery platform for central nervous system (CNS) and renal diseases. Its core technology involves standardized, high-throughput 'neuroloid' and kidney organoid models that mimic human tissue development and disease, enabling quantitative screening of compounds and genetic perturbations. By integrating human biology with artificial intelligence, Rumi aims to de-risk drug discovery, identify novel targets, and build an internal therapeutic pipeline, positioning itself at the intersection of stem cell biology, physics, and data science.

View full company profile

Therapeutic Areas

Central Nervous System Renal

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Somatic Expansion Inhibitor Program	LoQus23 Therapeutics	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active